| 摘要: |
| 目的：观察芩连二母散预防卡瑞利珠单抗免疫治疗晚期食管鳞癌致反应性皮肤毛细血管增生症（reactive cutaneous capillary endothelial proliferation，RCCEP）的临床疗效。方法：将58 例晚期食管鳞癌患者随机分为治疗组和对照组，每组各29 例，对照组予以卡瑞利珠单抗为基础的抗肿瘤治疗方案，治疗组在对照组基础上口服芩连二母散免煎颗粒。比较2组RCCEP的发生率、发生时间、分级及治疗前后的中医证候积分。结果：RCCEP发生率治疗组为34.48%（10/29），低于对照组的72.41%（21/29），差异有统计学意义（P＜0.05）；治疗组RCCEP发生时间较对照组延后，RCCEP分级优于对照组，治疗后中医证候积分低于对照组，差异均有统计学意义（P＜0.05或P＜0.01）。结论：芩连二母散预防卡瑞利珠单抗免疫治疗晚期食管鳞癌所致RCCEP具有良好疗效，在降低RCCEP发生率及临床分级、延缓发病时间方面均具有一定临床应用价值。 |
| 关键词: 晚期食管鳞癌 反应性皮肤毛细血管增生症 芩连二母散 卡瑞利珠单抗 |
| DOI： |
|
|
| Clinical effect of Qinlian Ermu powder in preventing reactive cutaneous capillary endothelial proliferation caused by camrelizumab in the treatment of advanced esophageal squamous cell carcinoma：An analysis of 29 cases |
| TANG Weiguo,XU Juanjuan,DAI Yongzhou |
| (The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine，Chengdu 610075，Sichuan，China) |
| Abstract: |
| Objective：To investigate the clinical effect of Qinlian Ermu powder in preventing reactive cutaneous capillary endothelial proliferation （RCCEP) caused by camrelizumab in the treatment of advanced esophageal squamous cell carcinoma.Methods：A total of 58 patients with advanced esophageal squamous cell carcinoma were randomly divided into treatment group and control group，with 29 patients in each group.The patients in the control group were given camrelizumab-based antitumor treatment regimen，and those in the treatment group were given oral administration of decocting-free granules of Qinlian Ermu powder in addition to the treatment in the control group.The two groups were compared in terms of the incidence rate，time of onset，and grading of RCCEP and traditional Chinese medicine （TCM) syndrome score before and after treatment.Results：The treatment group had a significantly lower incidence rate of RCCEP than the control group ［34.48% （10/29) vs 72.41% （21/29)，P＜0.05］，and compared with the control group，the treatment group had a significantly longer time to the onset of RCCEP，a significantly better grade of RCCEP，and a significantly lower TCM syndrome score after treatment （P < 0.05 or P < 0.01).Conclusion：Qinlian Ermu powder has a marked clinical effect in preventing RCCEP caused by camrelizumab in the treatment of advanced esophageal squamous cell carcinoma，with a certain clinical application value in reducing the incidence rate and clinical grade of RCCEP and delaying the time of onset. |
| Key words: advanced esophageal squamous cell carcinoma reactive cutaneous capillary endothelial proliferation Qinlian Ermu powder camrelizumab |
